USSTOCK.TODAY
Weekend. Closed Log in Sign up

Day One Biopharmaceuticals Inc(DAWN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

Halted
Trading Halted Since 2026-06-04: Trading has been halted. It may resume, and prices shown reflect the last trading day.
DAWN
DAWN
Halted
Day One Biopharmaceuticals Inc
$21.53
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -1.04Insider Own ⓘ 12.31%Shs Outstand ⓘ 103.0MPerf Week ⓘ -
Market Cap ⓘ 2.22BForward P/E ⓘ -EPS next Y ⓘ 78.57%Insider Trans ⓘ -0.5%Shs Float ⓘ 90.6MPerf Month ⓘ 0.42%
Enterprise Value ⓘ 1.79BPEG ⓘ -EPS next Q ⓘ -0.11Inst Own ⓘ 67.73%Short Float ⓘ 7.26%Perf Quarter ⓘ 105.44%
Income ⓘ -0.11BP/S ⓘ 14.06EPS this Y ⓘ 59.62%Inst Trans ⓘ -10.28%Short Ratio ⓘ 1.66Perf Half Y ⓘ 194.93%
Sales ⓘ 0.16BP/B ⓘ 5.03EPS next 5Y ⓘ -ROA ⓘ -19.68%Short Interest ⓘ 6.58MPerf YTD ⓘ 131.01%
Book/sh ⓘ 4.28P/C ⓘ 5.04EPS past 3/5Y ⓘ 21.77% -9.72%ROE ⓘ -22.74%52W High ⓘ 0% ($21.53)Perf Year ⓘ 193.72%
Cash/sh ⓘ 4.27P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -24.18%52W Low ⓘ 282.08% ($5.64)Perf 3Y ⓘ 57.15%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ -0.47%Gross Margin ⓘ 89.12%Volatility(W/M) ⓘ 0.11% 0.16%Perf 5Y ⓘ -
Dividend TTM ⓘ -EV/Sales ⓘ 11.29Sales Y/Y TTM ⓘ 20.6%Oper. Margin ⓘ -80.76%ATR (14) ⓘ 0.17Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 7.91EPS Q/Q ⓘ 68.21%Profit Margin ⓘ -67.85%RSI (14) ⓘ 80.32Recom ⓘ 3
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 8.02Sales Q/Q ⓘ 83.92%SMA20 ⓘ 0.36% ($21.45)Beta ⓘ -1.64Target Price ⓘ $21.5
Payout ⓘ -Debt/Eq ⓘ 0.01Earnings ⓘ 2026/2/24SMA50 ⓘ 19.55% ($18.01)Rel Volume ⓘ 0Prev Close ⓘ $21.53
Employees ⓘ 178LT Debt/Eq ⓘ 0.01EPS/Sales Surpr. ⓘ -41.03% 7.75%SMA200 ⓘ 102.18% ($10.65)Avg Volume(3M) ⓘ 3.97MPrice ⓘ $21.53
IPO ⓘ 2021/5/27Option/Short ⓘ Yes/NoTrades ⓘ 0Volume ⓘ -Change ⓘ -
Company
DAWN DAWNDay One Biopharmaceuticals Inc | NASD | Biotechnology Deep dive

🧠 This is a commercial-stage biopharmaceutical company revolutionizing the treatment of pediatric brain tumors. It has successfully established 'Ojemda' in the market—the world's first treatment for pediatric low-grade glioma (pLGG)—and is preparing for a new leap forward following its recent acquisition by the global pharmaceutical company Servier.

Quote

Over the past 1 year, on the higher side

0% below its 1-year high.

Now $21.53
52w low$5.6452w high$21.53
52W Range100%
Volume ⓘ 0

Traded less than usual. That is 0% of its average volume.

B
Overall · fairly good
We judged 6 of the 8 questions below. 3 rate excellent and 1 need caution.
No data for earnings, dividends, or not applicable.
ETFs holding this stock 5 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #83 of 599 in the industry

Based on market cap of $2B.

FAQ

FAQ

DAWN belongs to the Healthcare sector and operates in the Biotechnology industry.

The market cap of DAWN is approximately $2.2B, ranking 1,995 within its sector.

DAWN has recorded a 52-week high of $21.53 and a low of $5.64.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels